Research programme: Alzheimer's disease therapeutics - Alzinova

Drug Profile

Research programme: Alzheimer's disease therapeutics - Alzinova

Alternative Names: ALZ-101; ALZ-102; ALZ-103; ALZ-201; ALZ-301

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alzinova
  • Class Alzheimer vaccines; Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in Sweden (Parenteral)
  • 19 Dec 2011 Preclinical trials in Alzheimer's disease in Sweden (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top